Shock is associated with high mortality.

Emergency revascularization for CS has improved survival. However, the 35-45% 30-day mortality rate with PCI has persisted for decades despite advances in anti-thrombotic pharmacology and PCI techniques.

Multi-vessel PCI is associated with worse outcomes in MI and cardiogenic shock.

In the CULPRIT-SHOCK study of patients with acute MI, multi-vessel coronary artery disease, and CS, the 30-day risk of a composite of death or severe renal failure was higher among those who underwent multi-vessel PCI in comparison to infarct-artery PCI only. Trials are warranted to test novel strategies that may reduce mortality in patients with MI, multi-vessel CAD, and CS.

Non-randomized data suggest potential benefit from complete revascularization and cardioprotective measures employed with CABG in patients with multi-vessel CAD and CS.

We are in the early stages of planning a randomized trial of initial infarct-only PCI versus multi-vessel CABG with/without IRA reperfusion (mechanical thrombectomy and/or POBA) in patients with MI, multi-vessel CAD, and CS. Your responses to the questions below will help to guide study design.

Loading... Loading...
You have selected an option that triggers this survey to end right now. To save your responses and end the survey, click the button below to do so. If you have selected the wrong option by accident and do not wish to leave the survey, you may click the other button below to continue, which will also remove the value of the option you just selected to allow you to enter it again and continue the survey.
The response has now been removed for the last question for which you selected a value. You may now enter a new response for that question and continue the survey.